IS (C38435/120940)

Docket No.: 20731 US (C38435/120940)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

)

In re Application of :

Serial No.: 09/938,035

Examiner: not yet assigned

Filed: August 23, 2001

Art Unit: 1472

For MICROBIAL PROCESS FOR

PRODUCING L-ASCORBIC ACID, D-ERYTHORBIC ACID, AND SALTS

THEREOF

New York, New York September 27, 2001

REQUEST FOR A CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Sir:

Please issue and send us a corrected filing receipt. A copy of the filing receipt we recently received for this case is enclosed, with the error noted thereon. The error in the filing receipt is as follows:

The foreign applications information is incorrect. Therefore, please change "001180590.5 09/23/2000" to --00118059.5 08/23/2000--.

Appropriate correction is requested.

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center Washington, D.C. 20231, on September 27, 2001.

Kevin C. Hooper, Reg. No. 40,402

Respectfully submitted,

By:

Kevin C. Hooper

Registration No. 40,402

BRYAN CAVE LLP

245 Park Avenue

New York, NY 10167-0034

(212) 692-1800

Fax: (212) 692-1900

DUITED STATES PATENT AND TRADEMARK OFFICE

272r

WASHINGTON, D.C. 20231 UNITED STATES PATENT AND TRADEMARK OFFICE

GRP ART UNIT | FIL FEE REC'D | ATTY DOCKET NO | DRAWINGS | TOT CLAIMS | IND CLAIMS

20731/120940

ORIGINAL

1991

FILING DATE APPLICATION NUMBER

08/23/2001

980,886/60

CONFIRMATION NO. 1662

COMMISSIONER FOR PATENTS

*CC00000000000000 FILING RECEIPT New York, NY 10167-0034 245 Park Avenue Bryan Cave, LLP Stephen M. Haracz, Esq.

Date Mailed: 09/18/2001

generate another Filing Receipt incorporating the requested corrections (if appropriate). Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be

Applicant(s)

Masako Shinjoh, Kamakura-shi, JAPAN; Tatsuo Hoshino, Kamakura-shi, JAPAN; Akira Asakura, Fujisawa-shi, JAPAN;

ROCHE VITAMINS AG; Assignment For Published Patent Application

Domestic Priority data as claimed by applicant

EUROPEAN PATENT OFFICE (EPO) 00118059 5 6/23/2000 03 Foreign Applications

If Required, Foreign Filing License Granted 09/18/2001

Projected Publication Date: To Be Determined - pending completion of Sequence Disclosures

Non-Publication Request: No

Early Publication Request: No

ALAYOOC

Microbial process for producing L-ascorbic acid, D-erythorbic acid, and salts thereof

9lliT

Preliminary Class

Date: 09/18/2001

Team: OIPE

Data entry by : AMARE, TSION

984

LICENSE FOR FOREIGN FILING UNDER Title 35, Unit d States Code, S ction 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center ED
Washington, DC 20231

OATE

P - 2 9 - 2 00 /